Accordingly, empagliflozin [a sodium-glucose cotransporter 2 (SGLT2) inhibitor] known to exert nephroprotective effects and to slow down the decrease of the glomerular filtration rate in diabetic and non-diabetic patients with chronic kidney disease, was administered to the knock-in mice. Here, SLC5A2 is linked to chronic kidney disease.